DBV Technologies

Research DBV Technologies (DBVT) on Bullrun: market cap USD 946.93M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerDBVT
• ExchangeNASDAQ
• CountryFrance
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 946.93M
• Financial periodFY2025
• RevenueUSD 5.64M
• Revenue growth35.8%
• Net income-USD 146.95M
• Free cash flow-USD 121.71M

Valuation Snapshot

latest market cap is USD 946.93M.

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

Frequently asked questions

What is DBV Technologies's market cap?

DBV Technologies's market capitalization is USD 946.93M.

What does DBV Technologies do?

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.